TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression
Cancer Science · 2025
DOI: 10.1111/cas.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Takashi Yokoyama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Graduate School of Medicine, University of Yamanashi, Chuo, Japan. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Transforming Growth Factor beta, Aldehyde Dehydrogenase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The transforming growth factor‐β (TGF‐β)/Smad signaling pathway promotes malignant transformation through various mechanisms, and its effect on enhancing drug resistance can limit the efficacy of treatment. Here, we showed that pre‐stimulation of human lung cancer A549 cells with TGF‐β increases resistance to doxorubicin‐induced growth inhibition in a Smad3‐ and Smad4‐dependent manner. This effect was suppressed by the aldehyde dehydrogenase (ALDH) inhibitor oxyfedrine, suggesting that ALDH family members are involved in drug resistance. TGF‐β upregulated the mRNA and protein expression of ALDH1A1. The TGF‐β/Smad3 transcriptional enhancer region on ALDH1A1 was identified by Smad3 ChIP‐seq analysis using an open database and by reporter assays. Knockdown of ALDH1A1 in A549 cells suppressed TGF‐β–induced doxorubicin resistance, and lentivirus‐mediated introduction of ALDH1A1 into A549 SMAD3 ‐KO cells restored drug resistance. We also demonstrated that ALDH1A1 is required and sufficient for TGF‐β/Smad3 signaling–induced anchorage‐independent growth. The results suggest that the TGF‐β/Smad3/4 axis promotes resistance to doxorubicin and anchorage‐independent growth by inducing the transcription of ALDH1A1 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
- Center for Medical Education and Sciences, Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
ORCID-Profile: Takashi Yokoyama, Keiji Miyazawa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yokoyama, T., Saitoh, M., & Miyazawa, K. (2025). TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression. Cancer Science. https://doi.org/10.1111/cas.70109
Vancouver
Yokoyama T, Saitoh M, Miyazawa K. TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression. Cancer Science. 2025. doi:10.1111/cas.70109
BibTeX
@article{Yokoyama2025,
author = {Yokoyama, Takashi and Saitoh, Masao and Miyazawa, Keiji},
title = {TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70109}
}
EUVIMED